Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 19/20 | 0.43 |
| ▸ | FLT1 | P17948 | 1/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.43 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4130612 | 0.92 | FLT1 (0.43) | MAPK14FLT1MAPK11MINK1 | |
| Hydrochloric Acid SCHEMBL4072086 | 0.90 | MAPK14 (0.44) | MAPK14FLT1MAPK11MINK1 | |
| SCHEMBL13946414 | 0.83 | FLT1 (0.41) | MAPK14FLT1MAPK11MINK1 | |
| Hydrochloric Acid SCHEMBL4076151 | 0.82 | MAPK14 (0.42) | MAPK14FLT1MAPK11MINK1 | |
| Bromide SCHEMBL4206276 | 0.82 | FLT1 (0.40) | MAPK14FLT1MAPK11MINK1 | |
| SCHEMBL4206140 | 0.78 | PTGER1 (0.40) | MAPK14FLT1MAPK11MINK1 | |
| SCHEMBL10364829 | 0.77 | FLT1 (0.46) | MAPK14FLT1MAPK11MINK1 | |
| Hydrochloric Acid SCHEMBL4082863 | 0.77 | MAPK14 (0.44) | MAPK14FLT1MAPK11MINK1 | |
| SCHEMBL5764666 | 0.76 | MAPK14 (0.42) | MAPK14FLT1MAPK11MINK1 | |
| SCHEMBL4079593 | 0.76 | MAPK14 (0.40) | MAPK14FLT1MAPK11MINK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076356-B2 | Triazolopyridinylsulfanyl derivatives as P38 map kinase inhibitors | PFIZER INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-20090239899-A1 | Triazolopyridinylsulfanyl Derivatives As P38 Map Kinase Inhibitors | PFIZER INC. | 2009-09-24 | — | — | US | disclosed |
| US-7511057-B2 | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors | PFIZER INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-20060035922-A1 | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors | PFIZER INC. | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035922-A1 | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors | MAPK1, MAPKAPK5, MAPKAPK3 | MAPK14 24/4885FLT1 2821/4885MAPK11 38/4885 |
| US-20090239899-A1 | Triazolopyridinylsulfanyl Derivatives As P38 Map Kinase Inhibitors | MAPK1, MAPKAPK5, MAPKAPK3 | MAPK14 24/4885FLT1 2739/4885MAPK11 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.